$AKTX Cashflow Statement | Understand Stock

$AKTX

$7.63 -$0.59 (7.23%) Close

$AKTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Financing expense
Issuance of shares for services
Excess fair value of warrant liability over cash proceeds
Accretion of debt issuance costs
Gain on settlement of current liabilities
Loss on debt extinguishment
Change in fair value of warrant liabilities
Impairment loss on other intangible assets
Loss on derivative liability
Deferred income tax benefit
Unrealized foreign currency exchange losses (gains)
Change in assets and liabilities, net of acquisition of Peak Bio:
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Total adjustments
Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired in Peak Bio Acquisition
Net cash provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net of issuance costs
Proceeds for future exercises of warrants to purchase shares
Proceeds from issuance of warrants
Proceeds from issuance of notes payable
Proceeds from issuance of convertible notes
Repayment of convertible notes
Repayment of notes payable and convertible notes
Proceeds from issuance of restricted shares
Proceeds from employee vesting of restricted shares
Proceeds from pre-funded warrants
Payments on seller-financed purchases
Net cash provided by financing activities

Effect of exchange rates on cash
Net change in cash
Cash and restricted cash at beginning of period
Cash and restricted cash at end of period
Financing costs in accrued expenses
Ordinary share subscription deposit
Initial valuation of warrant liability
Components of cash and restricted cash
Cash
Restricted cash
Total cash and restricted cash
Financing costs in accounts payable and accrued expenses
Seller-financed purchases
Payroll taxes on stock-based compensation in accrued expenses
Issuance of ordinary shares for Peak Bio Acquisition
Warrants assumed in connection with Peak Bio Acquisition
SUPPLEMENTAL DISCLOSURES OF NON-CASH ACTIVITIES:
Financing costs in accounts payable and accrued expenses
Seller-financed purchases
Issuance of share capital for settlement of convertible notes, related party
Issuance of share capital for settlement of related party debt
Issuance of share capital for payments in kind
Modification of warrants in connection with issuance of notes payable
Modification of warrants in connection with amendment of convertible notes
Issuance of warrants in connection with note exchange and cancellation
Payroll taxes on stock-based compensation in accrued expenses
Issuance of ordinary shares for Peak Bio Acquisition
Warrants assumed in connection with Peak Bio Acquisition
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest

Comments